J. Ambler

发表

CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests

R. Humphries, J. Ambler, S. Mitchell, 2018, Journal of Clinical Microbiology.

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.

J. Ambler, R. Alm, R. Mclaughlin, 2015, The Journal of antimicrobial chemotherapy.

Efficacy of moxifloxacin for treatment of penicillin‐, macrolide‐ and multidrug‐resistant Streptococcus pneumoniae in community‐acquired pneumonia

J. Ambler, A. Torres, C. Fogarty, 2005, International journal of clinical practice.

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

J. Ambler, R. Schuch, J. Oh, 2021, Antimicrobial agents and chemotherapy.

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity

J. Ambler, M. Traczewski, R. Schuch, 2021, Journal of clinical microbiology.

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae

J. Ambler, L. Fisher, S. Mehtar, 1996, Antimicrobial agents and chemotherapy.

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

J. Ambler, J. Moore, C. Goldsmith, 1998, The Journal of antimicrobial chemotherapy.

Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.

J. Ambler, A. Sucari, J. Smayevsky, 2001, International journal of antimicrobial agents.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.

Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).

J. Ambler, C. Taylor, P. Hawkey, 2002, The Journal of antimicrobial chemotherapy.

Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro

J. Ambler, L. Fisher, V. J. Heaton, 2000, Antimicrobial Agents and Chemotherapy.

Antibiotic Drug Development: Moving Forward into the Clinic

J. Ambler, G. Stone, 2012 .

Potent Antipneumococcal Activity of Gemifloxacin Is Associated with Dual Targeting of Gyrase and Topoisomerase IV, an In Vivo Target Preference for Gyrase, and Enhanced Stabilization of Cleavable Complexes In Vitro

J. Ambler, L. Fisher, V. J. Heaton, 2000, Antimicrobial Agents and Chemotherapy.

Activity of Gemifloxacin against Penicillin- and Ciprofloxacin-Resistant Streptococcus pneumoniae Displaying Topoisomerase- and Efflux-Mediated Resistance Mechanisms

J. Ambler, L. Fisher, C. Goldsmith, 1999, Antimicrobial Agents and Chemotherapy.

Evaluation of CHROMagar candida for rapid identification and Etest for antifungal susceptibility testing in a district general hospital laboratory

J. Ambler, Y. Drabu, A. Yaneza, 2001, Journal of clinical pathology.

In Vitro Activity of Gemifloxacin (SB-265805) Compared to Eleven Other Antimicrobial Agents Against Streptococcal Isolates, Excluding Streptococcus pneumoniae

J. Ambler, Y. Drabu, P. Lee, 2001, European Journal of Clinical Microbiology and Infectious Diseases.

Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.

J. Ambler, S. Gillespie, A. Dickens, 2003, Microbial drug resistance.

Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines.

J. Ambler, L. Koeth, R. Rennie, 2008, Diagnostic microbiology and infectious disease.

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model

J. Ambler, Renu Singh, R. Alm, 2017, The Journal of antimicrobial chemotherapy.

Detection of Antigenic Cross-Reactivity Between Helicobacter Pylori and other Bacteria by Inhibition Elisa

J. Ambler, S. Mehtar, Y. Drabu, 1996 .

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program

J. Ambler, R. Alm, D. Hoban, 2015, Antimicrobial Agents and Chemotherapy.